All In Biotech

Drug Trial Radar · NCT04580134

CLOZAPINE Response in Biotype-1

Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 524 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

524

Planned (sponsor's estimate)

Start

Mar 1, 2022

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Mental Health (NIMH); Beth Israel Deaconess Medical Center; Hartford Hospital; University of Georgia; University of Chicago
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar 1 Disorder

Interventions

  • clozapineDrug

    Biotype 1 and Biotype 2

  • risperidoneDrug

    Biotype 1 and Biotype 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the PANSS total scoreTime frame: Week 4, Week 10 and Week 18

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Hartford Healthcare

    Hartford, Connecticut · Recruiting

  • University of Georgia

    Athens, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.